Fourth study published over two-year span that analyzes key leukemia protein
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia “super drug” to test on humans in a clinical trial.
The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.
30%Current survival rate for pediatric leukemia patients.
“These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients,” said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern’s Simpson Querrey Center for Epigenetics. “This is a monster cancer that we’ve been dealing with for many years in children.”
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
For the past 25 years, Shilatifard’s laboratory has been studying the molecular function of MLL within its complex known as COMPASS (Complex Proteins Associated with Set1). Most recently, it was demonstrated that COMPASS components are one of the most frequently identified mutations in cancer.The next step of this work will be to bring the drug to a clinical trial setting, which Shilatifard said he hopes will happen in the next three to five years.
“I’ve been working on this translocation for more than two decades, and we’re finally at the point where in five to 10 years, we can get a drug in kids that can be effective,” Shilatifard said. “If we can bring that survival rate up to 85 percent, that’s a major accomplishment.”
Earlier work from Shilatifard’s laboratory published in Cell in 2018 identified compounds that could slow cancer growth by interrupting a gene transcription process known as “Super Elongation Complex” (SEC). It was the first compound in its class to do this.
This MLL stabilization process discovered in the most recent paper could potentially work in cancers with solid tumors, such as breast or prostate cancer, said first author Zibo Zhao, a postdoctoral research fellow in Shilatifard’s lab.
“This opens up a new therapeutic approach not only for leukemia, which is so important for the many children who are diagnosed with this terrible cancer, but also for other types of cancers that plague the population,” Zhao said.
“The publication of these four papers and the possibility of a future human clinical trial could not have happened if it weren’t for the cross-disciplinary collaboration at Northwestern,” Shilatifard said.
The Latest on: Pediatric leukemia
via Google News
The Latest on: Pediatric leukemia
- Clemson players meet teen battling leukemia at National Championship gameon January 12, 2020 at 2:13 pm
Jackson was able to bring his entire family to the big game as part of his Make-A-Wish trip. Jackson has leukemia and has been getting treatment for about a year and a half. Children around the ...
- Dr Lena Winestone Outlines Barriers to Care and Disparities Among Children With Leukemiaon January 12, 2020 at 5:09 am
Financial barriers and perceived implicit biases were both barriers that families of children with acute leukemia raised regarding access to care issues that might have delayed diagnosis, said Lena ...
- Cancer Advances Too Often Ignore Childrenon January 9, 2020 at 2:34 pm
Children are in danger of being left behind when it comes to cancer research. There has been plenty of good news on this front. It was just announced that the cancer death rate in 2017 in the United ...
- Dr Sarah Tasian Highlights Exciting New Advances Coming to Pediatric AMLon January 9, 2020 at 2:21 pm
that she is the most excited for. Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
- Survivors of childhood acute lymphoblastic leukemia at higher risk for type 2 diabeteson January 9, 2020 at 11:53 am
Survivors of childhood acute lymphoblastic leukemia, particularly those with obesity and/or who received treatment during adolescence, appeared to be at higher risk for type 2 diabetes than the ...
- Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemiaon January 8, 2020 at 4:13 pm
Acute myeloid leukemia (AML) is a genetically heterogeneous disease that accounts for about 20% of pediatric leukemia. The overall 5-year survival rate for pediatric patients with AML has increased ...
- Burlington Stores Raises More Than $5.8 Million For The Leukemia & Lymphoma Society This Yearon January 7, 2020 at 5:00 am
- Criss Angel shaves 5-year-old son’s head in tender video in midst of leukemia returnon January 3, 2020 at 9:47 am
Illusionist Criss Angel is getting candid about his young son’s cancer battle, after revealing last month that the 5-year-old’s leukemia had returned ... where he’s triumphantly donning a red cape ...
- Criss Angel Shares Video Shaving His 5-Year-Old Son’s Head Amid Leukemia Relapseon January 2, 2020 at 2:30 pm
In December, the illusionist learned that his five-year-old son Johnny Crisstopher’s cancer has returned. Johnny was diagnosed with acute lymphoblastic leukemia in 2015. Childhood acute lymphoblastic ...
- Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics market statistical analysis 2020|CAGR growth of 2020 and forecast to 2023on January 2, 2020 at 8:56 am
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market 2020 report points out to all the major trends of market, it's share, market division, market outlook and a keen analysis of Acute ...
via Bing News